HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $80.
July 30, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics and maintained a price target of $80, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Celldex Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100